Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Wenjie Liu [1 ]
Yuting Fang [1 ]
Chao Zhang [2 ]
Midan Xiang [1 ]
Lijuan Qi [3 ]
Aijiang Su [2 ]
Yongkun Sun [1 ]
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center
[2] Beijing Chaoyang District Sanhuan Cancer Hospital,Department of Medical Oncology
[3] Chinese Academy of Medical Sciences,National Cancer Center, National Clinical Research Center for Cancer/Hebei Cancer Hospital
来源：
BMC Gastroenterology | / 25卷 / 1期
关键词：
Metastatic pancreatic ductal adenocarcinoma; NALIRIFOX; Nab-paclitaxel and gemcitabine; Cost-effectiveness;
D O I：
10.1186/s12876-025-03867-2
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    De Jesus-Acosta, Ana
    Sugar, Elizabeth A.
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Rasheed, Zeshaan
    Zheng, Lei
    Begum, Asma
    Anders, Robert
    Maitra, Anirban
    McAllister, Florencia
    Rajeshkumar, N. V.
    Yabuuchi, Shinichi
    de Wilde, Roeland F.
    Batukbhai, Bhavina
    Sahin, Ismet
    Laheru, Daniel A.
    BRITISH JOURNAL OF CANCER, 2020, 122 (04) : 498 - 505
  • [32] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Jaime Feliu
    Mónica Jorge Fernández
    Teresa Macarulla
    Bartomeu Massuti
    Ana Albero
    José Federico González González
    Guillermo Quintero-Aldana
    Juan Ignacio Delgado-Mingorance
    Ana Fernández Montes
    Carmen García Piernavieja
    Manuel Valladares-Ayerbes
    Ana María López Muñoz
    Rebeca Mondéjar Solís
    Pilar Vicente
    Esther Casado Gonzalez
    Irene González Cebrián
    Guillermo López-Vivanco
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 543 - 553
  • [33] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [34] RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
    Lim, Kian-Haut
    Hidalgo, Manuel
    O'Hara, Mark H.
    Spencer, Kristen R.
    Garrido-Laguna, Ignacio
    DeNardo, David G.
    Bhambhani, Vijeta
    Patrick, Gloria
    Cheng, Yaofeng
    Coma, Silvia
    Pachter, Jonathan A.
    Denis, Louis J.
    CANCER RESEARCH, 2024, 84 (02)
  • [35] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    Ana De Jesus-Acosta
    Elizabeth A. Sugar
    Peter J. O’Dwyer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Zeshaan Rasheed
    Lei Zheng
    Asma Begum
    Robert Anders
    Anirban Maitra
    Florencia McAllister
    N. V. Rajeshkumar
    Shinichi Yabuuchi
    Roeland F. de Wilde
    Bhavina Batukbhai
    Ismet Sahin
    Daniel A. Laheru
    British Journal of Cancer, 2020, 122 : 498 - 505
  • [36] Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
    Kimmie Ng
    Andrew Hendifar
    Alexander Starodub
    Jorge Chaves
    Yingsi Yang
    Brian Koh
    David Barbie
    William C. Hahn
    Charles S. Fuchs
    Investigational New Drugs, 2019, 37 : 159 - 165
  • [37] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Feliu, Jaime
    Jorge Fernandez, Monica
    Macarulla, Teresa
    Massuti, Bartomeu
    Albero, Ana
    Gonzalez Gonzalez, Jose Federico
    Quintero-Aldana, Guillermo
    Ignacio Delgado-Mingorance, Juan
    Fernandez Montes, Ana
    Garcia Piernavieja, Carmen
    Valladares-Ayerbes, Manuel
    Lopez Munoz, Ana Maria
    Mondejar Solis, Rebeca
    Vicente, Pilar
    Casado Gonzalez, Esther
    Gonzalez Cebrian, Irene
    Lopez-Vivanco, Guillermo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 543 - 553
  • [38] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [39] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2018, 36 : 96 - 102
  • [40] Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel plus gemcitabine in metastatic pancreatic ductal adenocarcinoma
    Baron, Kelsey
    Nevala-Plagemann, Christopher Duane
    Moser, Justin
    Haaland, Benjamin
    Wang, Xuechen
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345